Prospective study of fibrinolytic factors and incident coronary heart disease: The atherosclerosis risk in communities (ARIC) study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 4, 2001, Pages 611-617

  Folsom, Aaron R ^a   Aleksic, Nena ^b   Park, Eunsik ^c   Salomaa, Veikko ^d   Juneja, Harinder ^b   Wu, Kenneth K ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c IL   (United States)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Coronary disease; Fibrinolysis; Risk factors

Indexed keywords

ANTIGEN; D DIMER; FIBRINOLYTIC FACTOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIGEN DETECTION; ARTICLE; ATHEROSCLEROSIS; FEMALE; FIBRINOLYSIS; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PLASMINOGEN ACTIVATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 0035051534     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.4.611     Document Type: Article

References (47)

1. The plasminogen (fibrinolytic) system
2. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
3. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris
4. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
5. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
6. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
7. Thrombogenic factors and recurrent coronary events
8. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants
9. Fibrinogen as a risk factor for stroke and myocardial infarction
10. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
11. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
12. Fibrinolytic activity and clotting factors in ischaemic heart disease in women
13. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
14. Prospective study of endogenous tissue plasminogen activator and risk of stroke
15. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
16. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
17. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
18. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
19. Fibrinolytic activation markers predict myocardial infarction in the elderly: The Cardiovascular Health Study
20. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
21. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease: A nested case-control study
22. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives
23. A short questionnaire for the measurement of habitual physical activity in epidemiological studies
24. High resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities Study (ARIC)
25. Association of transient ischemic attack/stroke symptoms assessed by standardized questionnaire and algorithm with cerebrovascular risk factors and carotid artery wall thickness: The ARIC Study, 1987-1989
26. ARIC Hemostasis Study, I: Development of blood collection and processing systems suitable for multicenter hemostatic studies
27. ARIC Hemostasis Study, II: Organizational plan and feasibility study
28. ARIC Hemostasis Study, IV: Intraindividual variability and reliability of hemostatic factors
29. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens
30. Reagent for the enzymatic determination of total serum cholesterol with improved lipolytic efficiency
31. 2+ precipitation
32. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency
33. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
34. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: Methods and initial two years' experience
35. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA
36. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
37. Plasminogen determination, using a chromogenic tripeptidic substrate
38. Monoclonal antibodies that react preferentially with fibrinogen degradation products or with cross-linked fibrin split products
39. Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay
40. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
41. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study
42. Robust variance estimation for the case-cohort design
43. Association of fibrinolytic parameters with early atherosclerosis: The ARIC Study
44. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
45. Thrombin, thrombomodulin, and TAFI in the molecular link between coagulation and fibrinolysis
46. Regulation of plasminogen gene expression by interleukin-6
47. Expression and induction by IL-6 of the normal and variant genes for human plasminogen